VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe ...

Every September, NYU faces scrutiny from a nonprofit organization that evaluates free speech and expression across U.S.

NYU once again received an ‘F’ grade on an annual list evaluating free speech policies across U.S. universities. The ranking, ...

Views Staff Writer Alaina Babb argues that elocution builds clarity and confidence, making it a crucial but forgotten skill ...

Sometimes we don’t realize how family dynamics affect us until we step back and take a closer look. It's easy to get caught ...

Middle age might just be life’s most fascinating plot twist. It’s that eye-opening chapter where people start noticing subtle ...

Discover a study using CD206-targeted imaging to predict immunotherapy response and outcomes in patients with advanced ...

When we think of public health infrastructure, hospitals and community health clinics often come to mind. But what about ...

PsiQuantum proposed the build in November 2022, and its ultimately successful Brisbane plan — backed by around $1 billion in ...

A phase 1/2 study is currently underway to evaluate SAR446268 in participants aged 10 to 50 years with non-congenital myotonic dystrophy type 1.